Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Measures of cognitive functioning appropriate for use in pediatric psychopharmacological research studies.

Swanson JM.

Psychopharmacol Bull. 1985;21(4):887-90. No abstract available.

PMID:
4089109
2.

Psychopharmacology and psychosomatic disorders.

Ban TA.

Psychosomatics. 1978 Dec;19(12):757-60. No abstract available.

PMID:
734030
3.

Psychopharmacology research for individuals with mental retardation: methodological issues and suggestions.

Matson JL, Bielecki J, Mayville SB, Matson ML.

Res Dev Disabil. 2003 May-Jun;24(3):149-57.

PMID:
12742384
4.

Perspectives in psychopharmacological neuroimaging.

Fusar-Poli P.

Curr Pharm Des. 2009;15(22):2533-4. No abstract available.

PMID:
19689325
5.

Time-dependent sensitization--possible implications for clinical psychopharmacology.

Antelman SM, Soares JC, Gershon S.

Behav Pharmacol. 1997 Nov;8(6-7):505-14; discussion 515-22. Review.

PMID:
9832965
6.

Drugs, biochemistry, and conscious experience: toward a theory of psychopharmacology.

Willner P.

Perspect Biol Med. 1984 Autumn;28(1):49-64. No abstract available.

PMID:
6514540
7.

Psychopharmacology research in the English-speaking Caribbean.

Jaime LK, Maharajh H.

Drug Metabol Drug Interact. 2000;16(1):69-81. Review.

PMID:
10820583
8.

Medication development and testing in children and adolescents. Current problems, future directions.

Vitiello B, Jensen PS.

Arch Gen Psychiatry. 1997 Sep;54(9):871-6. Review.

PMID:
9294379
9.

A brain function diagnostic and study unit for psychotropic drug development and psychopharmacology research.

Itil TM, Shapiro DM, Eralp E, Akman A, Itil KZ.

Psychopharmacol Bull. 1986;22(1):297-300. No abstract available.

PMID:
3726076
10.

[The possible participation of the visual apparatus in the psychopharmacological effect].

Arushanian EB, Ovanesov KB.

Eksp Klin Farmakol. 1997 Jul-Aug;60(4):76-82. Review. Russian.

PMID:
9376768
11.

A psychopharmacological perspective of cognitive functions. I. Theoretical overview and methodological considerations.

Wolkowitz OM, Tinklenberg JR, Weingartner H.

Neuropsychobiology. 1985;14(2):88-96. Review.

PMID:
3937068
12.

Child and adolescent psychopharmacology. Important developmental issues.

Tosyali MC, Greenhill LL.

Pediatr Clin North Am. 1998 Oct;45(5):1021-35, vii. Review.

PMID:
9884673
13.

Developmental perspectives in pediatric psychopharmacology.

Vitiello B, Jensen PS.

Psychopharmacol Bull. 1995;31(1):75-81. Review.

PMID:
7675993
14.

Drug-drug interactions in pediatric psychopharmacology.

Ten Eick AP, Nakamura H, Reed MD.

Pediatr Clin North Am. 1998 Oct;45(5):1233-64, x-xi. Review.

PMID:
9884684
15.

Pediatric psychopharmacology outside the U.S.A.

Simeon J, Utech C, Simeon S, Itil TM.

Dis Nerv Syst. 1974 Jul;35(7 Pt. 2):37-47.

PMID:
17894102
16.

Résumés of research projects in psychopharmacology.

[No authors listed]

Psychopharmacol Bull. 1980 Jan;16(1):68-78. No abstract available.

PMID:
7360849
17.

[Psychopharmacological agents as regulators of synaptic plasticity].

Komissarov IV, Abramets II.

Eksp Klin Farmakol. 1994 Sep-Oct;57(5):45-50. Review. Russian. No abstract available.

PMID:
7696907
18.

Pediatric psychopharmacology: current status.

Werry JS.

Ann Acad Med Singapore. 1980 Jan;9(1):107-17. Review. No abstract available.

PMID:
6108741
19.

Assessment of safety in pediatric psychopharmacology.

Greenhill LL.

J Am Acad Child Adolesc Psychiatry. 2003 Jun;42(6):625-6. No abstract available.

PMID:
12921468
20.

Supplemental Content

Support Center